Search results
Showing 7726 to 7740 of 8314 results
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.Retired guidance is no longer being actively maintained. The guidance has no status, and the health and care system is not expected to follow it. Retired guidance is available as a PDF for reference only.
Improving supportive and palliative care for adults with cancer (CSG4)
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.Retired guidance is no longer being actively maintained. The guidance has no status, and the health and care system is not expected to follow it. Retired guidance is available as a PDF for reference only.
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.Retired guidance is no longer being actively maintained. The guidance has no status, and the health and care system is not expected to follow it. Retired guidance is available as a PDF for reference only.
This guidance has been replaced by NICE guideline NG17.
Farco-fill Protect for indwelling urinary catheterisation (MIB121)
July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)
We have moved Diagnostics guidance 16 to become HealthTech guidance 360. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 13 to become HealthTech guidance 348. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 8 to become HealthTech guidance 315. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 9 to become HealthTech guidance 316. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
The NICE commercial liaison team aim to reduce the workload for the NHS and frontline staff by making commercial agreements more straightforward.
Past technology appraisal appeals and decisions
Research to access pathway for investigational drugs for COVID-19 (RAPID C-19)
RAPID C-19’s role in reviewing potential COVID-19 treatments has now ended because we have moved back to routine commissioning arrangements for these treatments.
NICE's business plan, annual report, charter, transformation story, gender pay gap report, framework agreement and other publications.
Appraisal is the process of determining which records have continuing business or historical value from those which have no further value and should be disposed of appropriately.
Home Implementing NICE guidance...